AMGEN INC - 19 Sep 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: 10%+ Owner
Issuer ticker: NMRA
Reported as of: 19 Sep 2023
Net transaction value: +$29,999,985
SEC form: 4
Accepted by SEC: 19 Sep 2023, 19:52:07 UTC
Prior SEC filing: 14 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Peter H. Griffith, Executive Vice President and Chief Financial Officer

Key filing fact

AMGEN INC filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 19 Sep 2023.

Key facts

This page summarizes AMGEN INC's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Sep 2023, 19:52.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: +$29,999,985.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NMRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +33,603,948
Change %
Price
Shares after: 33,603,948
Date: 19 Sep 2023
Ownership: Direct
Footnotes: F1

NMRA transaction

Common Stock

Purchase

Transaction value: $29,999,985
Shares: +1,764,705
Change %: +5.3%
Price: $17.00^*
Shares after: 35,368,653
Date: 19 Sep 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMRA transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -32,754,291
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,754,291
Exercise price
Footnotes: F1

NMRA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -849,657
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 849,657
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.